Variation Biotech lands US$37.5 million in financing

Guest Contributor
January 18, 2007

Ottawa-based Variation Biotechnologies Inc (VBI) has secured US$37.5 million in Series A financing to move its vaccine program into clinical development with an initial focus on influenza. Clarus Ventures is the lead investor in a syndicate including ARCH Venture Partners, 5AM Ventures and existing seed investors. Founded in 2001, the privately held firm has early-stage investments of $2.1 million in initial funding from the Industrial Research Assistance Program, Economic Development Canada and Investissement Quebec. VBI's founder and CEO is Dr Francisco Diaz-Mitoma. The firm's peptide-based Varosite vaccine platform is aimed at a wide array of pathogens with several applications slated to move into clinical development in the next two or three years....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.